statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Latest Ratings for RYTM
 DateFirmActionFromTo Mar 2022Canaccord GenuityMaintainsBuy Mar 2022NeedhamMaintainsBuy Feb 2022NeedhamMaintainsBuy
 View More Analyst Ratings for RYTM

 View the...

Analyst Expectations For Rhythm Pharmaceuticals's Future

5 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know

For the last three days, A.I.dvisor has detected that RYTM's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Rhythm Pharmaceuticals (RYTM, $42.67) Aroon Indicator entered a Downtrend on April 01, 2024.

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Rhythm Pharmaceuticals secures $150M in convertible preferred stock financing

Rhythm Pharmaceuticals gets $150M in convertible preferred stock financing...

Rhythm Pharmaceuticals gets $150M in convertible preferred stock financing

-- Proceeds from financing and existing cash on-hand sufficient to fund planned operations into 2026 --BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a...

Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing

With the business potentially at an important milestone, we thought we'd take a closer look at Rhythm Pharmaceuticals...

Analysts Expect Breakeven For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Before Long

This price move could be a signal that RYTM may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

Rhythm Pharmaceuticals (RYTM, $43.27) price may drop as it broke higher Bollinger Band on Mar 28, 2024

Rhythm Pharmaceuticals (RYTM, $43.27) Aroon Indicator entered a Downtrend on March 28, 2024.

This is a signal that RYTM's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

Rhythm Pharmaceuticals (RYTM, $43.27) Stochastic Oscillator left the overbought zone on March 28, 2024

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Volume	212,447.00
52-Wk High	$52.57
52-Wk Low	$15.50

Period	Estimated	Reported	Surprise	Result
Q1'24	-$2.36	--	--	N/A
Q4'23	-$0.71	-$0.70	0.79%	BEAT
Q3'23	-$0.74	-$0.76	-2.70%	MISSED
Q2'23	-$0.80	-$0.82	-2.79%	MISSED
Q1'23	-$0.72	-$0.92	-28.22%	MISSED

RYTM Rhythm Pharmaceuticals Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals